中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2018, Vol. 47 ›› Issue (11): 1011-1014.doi: 10.12007/j.issn.0258-4646.2018.11.012

• 论著 • 上一篇    下一篇

雷珠单抗玻璃体内注射、全视网膜光凝和黄斑光凝联合治疗糖尿病黄斑水肿的临床疗效

于秀玲, 徐丽, 刘驰   

  1. 沈阳市第四人民医院眼科, 沈阳 110031
  • 收稿日期:2018-03-12 出版日期:2018-11-30 发布日期:2018-12-06
  • 通讯作者: 徐丽 E-mail:xu-li1149@163.com
  • 作者简介:于秀玲(1971-),女,主任医师,博士.
  • 基金资助:
    沈阳市科学技术计划(F16-206-9-25)

Clinical Effect of Treatment with a Combination of Lucentis Intravitreal Injection and Whole Retinal and Macular Photo Coagulation in Patients with Diabetic Macular Edema

YU Xiuling, XU Li, LIU Chi   

  1. Department of Ophthalmology, The Fourth People's Hospital of Shenyang, Shenyang 110031, China
  • Received:2018-03-12 Online:2018-11-30 Published:2018-12-06

摘要: 目的 评价单纯玻璃体内注射雷珠单抗注射液、单纯采用全视网膜光凝联合黄斑格栅样光凝和玻璃体内注射雷珠单抗注射液联合全视网膜光凝同时黄斑格栅样光凝治疗糖尿病黄斑水肿(DME)的临床疗效。方法 通过光学相干断层扫描(OCT)和眼底荧光血管造影(FFA)筛选符合条件的DME患者(共60眼),随机分为3组:单纯注药组(开始时、4周、8周时注药),单纯激光组(全视网膜光凝同时黄斑格栅样光凝治疗)和玻璃体内注射雷珠单抗注射液联合全视网膜光凝同时黄斑格栅样光凝联合治疗组(联合治疗组,于注药1周行全视网膜光凝同时黄斑格栅样光凝治疗),每组各20眼。比较3组治疗后1周、4周、8周、12周的最佳矫正视力(BCVA)及黄斑中心凹视网膜厚度(CMT)变化。结果 联合治疗组注药后1、4、8、12周BCVA和CMT与术前及组间比较均有统计学差异(均P<0.05)。单纯注药组在相应时间点BCVA和CMT与术前比较有统计学差异(P<0.05),与单纯激光组8周内比较有统计学差异(P<0.05),12周2组间比较无统计学差异(P>0.05)。单纯激光组术后4周BCVA和CMT与术前比较无统计学差异(P>0.05),12周时与术前比较有统计学差异(P<0.05)。联合治疗组与单纯注药组治疗后与术前比较BCVA均明显提高;联合治疗组治疗后12周与8周时比较BCVA显著升高。单纯激光组术后4周内视力提高不明显,个别患者加重黄斑水肿、视力下降,但8周后与单纯注药组比较无明显差异。结论 玻璃体内注射雷珠单抗注射液联合全视网膜光凝同时黄斑格栅样光凝治疗DME能够有效提高患者视力,降低CMT。

关键词: 糖尿病视网膜病变/并发症, 黄斑水肿, 雷珠单抗, 全视网膜光凝, 黄斑格栅样光凝, 联合治疗

Abstract: Objective To evaluate the clinical effect,including best corrected visual acuity (BCVA),of lucentis intravitreal injection,photocoagulation,and combined lucentis intravitreal injection and photocoagulation,in patients with diabetic macular edema. Methods In total 42 patients (60 eyes) with edema were randomly divided into three groups:the combined group (treated with lucentis intravitreal injection and laser therapy),injection group (treated with lucentis intravitreal injection alone),and laser group (laser treatment alone). We compared the treatment effects among the three groups,including the impact on the central retinal thickness (CMT),and BCVA. Results After treatment for 1,4,8,and 12 weeks,the CMT and BCVA in the combined group and the injection group were significantly different from those before treatment (P<0.05,each). After treatment for 8,and 12 weeks,the CMT and BCVA in the laser group were significantly different from those before treatment (P<0.05,each). The BCVA in the combined group and the injection group were significantly higher than that before treatment. After treatment for 1 and 4 weeks,the BCVA in the laser group did not increase from that before treatment;moreover,the individual patients showed aggravated macular edema,resulting in decreased vision. After treatment for 8 weeks,the BCVA in the laser group did not increase significantly in comparison to the injection group. Conclusion The combination of lucentis intravitreal injection and laser treatment in patients with diabetic macular edema showed synergistic effects to significantly reduce macular edema-induced CMT and improve BCVA.

Key words: diabetic retinopathy/complication, macular edema, lucentis, panretinal photocoagulation, macular grid pattern photocoagulation, combined treatment

中图分类号: 

  • R587.2
[1] ZIMMET P,ALBERTI KG,SHAW J. Global and societal implications of the diabetes epidemic[J]. Nature,2001,414(6865):782-787. DOI:10.1371/journ.pone.0078536 Sep 09,2014.
[2] BURGESS PI,MACCORMICK IJC,HARDING SP,et al. Review article epidemiology of diabetic retinopathy and maculopathy in Africa:a systematic review[J]. Diabetes Med,2013,30(4):399-412. DOI:10.1111/j.1464-5491. 2012.03756.x.
[3] YAU JW,ROGERS SL,KAWASAKI R,et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care,2012,35(3):556-564. DOI:10.2337/dc.11-1909.
[4] Ocular Fundus Diseases Group of Chinese Ophthalmological Society. Guidelines for clinical diagnosis and treatment of diabetic retinopathy in china. (2014)[J].China J Ophthalmol,2014,50(11):851-865. DOI:10.3760/cma.j.issn.0412-4081.2014.11.014.
[5] 张珊珊.玻璃体腔内注射雷珠单抗治疗复发性糖尿病黄斑水肿疗效观察[J].国际眼科杂志,2015,15(9):1600-1602. DOI:10.3980/j.issn.1672-5123.2015.9.29.
[6] MASSIN P,BANDELLO F,GARWEG JG,et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESLOVE):a 12 month randomized,controlled,double-masked,muhicenter phaseⅡstudy[J].Diabetes Care,2010,33(11):2399-2405. DOI:10.3137/ao.430302.
[7] SACHDEVA MM,MOSHIRI A,LEDER HA,et al. Endophthalmitis following intravitreal injection of anti-VEGF agents:long-term outcomes and the identification of unusual micro-organisms[J]. J Ophthalmol Inflamm Infect,2016,6(1):2. DOI:10.1186/s12348-015-0069-5.
[8] 汪伟,万李,周季家,等. 糖尿病黄斑水肿的发病机制及治疗进展[J]. 国际眼科杂志,2009,9(3):525-527. DOI:10.3969/j.issn.1672-5123.2009.03.038.
[9] IP MS,BRESSLER SB,ANTOSZYK AN,et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema:baseline features[J].Retina,2008,28(7):919-930. DOI:10.1097/IAE.0b013e31818144a7.
[10] 程里礼,程秋霞,马建青,等. 雷珠单抗联合激光光凝对糖尿病黄斑水肿疗效的系统评价[J]. 分子影像学杂志,2017,40(4):430-435. DOI:10.3969/j.issn.1674-4500.2017.04.12.
[1] 梅同华,戴玲丽,张明川. PDCD5基因对顺铂在裸鼠A549肺癌中疗效的协同作用[J]. 中国医科大学学报, 2015, 44(11): 1002-1005.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA